<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21092" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Loeffler Endocarditis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mubarik</surname>
            <given-names>Ateeq</given-names>
          </name>
          <aff>Oak hill hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Iqbal</surname>
            <given-names>Arshad Muhammad</given-names>
          </name>
          <aff>Oak Hill Hospital, Brooksville, FL</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ateeq Mubarik declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arshad Muhammad Iqbal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21092.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Loeffler endocarditis is an uncommon restrictive cardiomyopathy associated with hypereosinophilic syndromes. Loeffler endocarditis is interchangeably referred to as eosinophilic endomyocardial disease or fibroblastic endocarditis. The condition, characterized by eosinophil-mediated cardiac damage, leads to restrictive cardiac disease, resulting in impaired heart relaxation and diastolic dysfunction. Clinical presentations of Loeffler endocarditis vary, including intracardiac thrombus, arrhythmia, or acute heart failure, with manifestations depending on the disease stage. Early diagnosis and vigilant follow-up&#x000a0;are crucial due to the disease's progressive nature and poor outcomes in the absence of intervention.</p>
        <p>This activity provides an in-depth review of Loeffler endocarditis, covering essential aspects such as pathophysiology, clinical manifestations, diagnostic modalities, and contemporary treatment approaches. Participants gain insights into the evaluation and management of Loeffler endocarditis&#x000a0;with a focus on the intricacies of this rare disorder. The collaboration of an interprofessional team can significantly impact competence in managing complex cardiovascular cases, including Loeffler endocarditis.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;clinical presentations and characteristic features of Loeffler endocarditis, fostering early and accurate diagnosis.</p></list-item><list-item><p>Apply&#x000a0;diagnostic modalities effectively in assessing and monitoring Loeffler endocarditis.</p></list-item><list-item><p>Assess&#x000a0;disease progression and treatment response, ensuring timely adjustments for optimal outcomes for patients with Loeffler endocarditis.</p></list-item><list-item><p>Coordinate&#x000a0;efforts among team members for streamlined and efficient management of Loeffler endocarditis, addressing its multifaceted challenges.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21092&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21092">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21092.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Loeffler endocarditis is an eosinophilic-mediated restrictive cardiomyopathy occurring as part of the spectrum of hypereosinophilic syndromes. First described by W. Loeffler in 1936, Loeffler endocarditis is associated with peripheral eosinophilia and is one of the rare complications of hypereosinophilic syndromes. Extensive eosinophilic infiltration and damage to multiple organs characterize hypereosinophilic syndromes.<xref ref-type="bibr" rid="article-21092.r1">[1]</xref> Loeffler endocarditis results in impaired heart relaxation with impaired diastolic filling.<xref ref-type="bibr" rid="article-21092.r2">[2]</xref>&#x000a0;</p>
        <p>The predominant pathology of Loeffler endocarditis is diffuse eosinophilic infiltration of the myocardium. Cardinal manifestations of Loeffler endocarditis include left or right heart failure, thromboembolic events (stroke, limb ischemia, renal infarction), or arrhythmia. Life-threatening clinical presentations warrant immediate initiation of therapy, including steroids or immunosuppressive therapy.<xref ref-type="bibr" rid="article-21092.r3">[3]</xref><xref ref-type="bibr" rid="article-21092.r4">[4]</xref>&#x000a0;Eosinophilic endomyocardial disease or fibroblastic endocarditis can be used interchangeably for Loeffler endocarditis. Endomyocardial fibrosis is a disease closely resembling the late stage of Loeffler endocarditis.&#x000a0;</p>
      </sec>
      <sec id="article-21092.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Loeffler endocarditis is a rare manifestation of hypereosinophilic syndromes (divided into idiopathic, primary, and secondary types based on the underlying etiology). Idiopathic hypereosinophilic syndromes are a rare entity with no apparent cause of elevated eosinophil count and are the most common cause of Loeffler endocarditis. Underlying myeloproliferative and stem cell disorders such as leukemia and lymphoma have been associated with the primary type of hypereosinophilic syndromes. Secondary&#x000a0;hypereosinophilic syndromes are reactive to an underlying non-neoplastic or paraneoplastic condition, including allergic conditions, parasitic, fungal infections, and tumors, causing the expansion of non-clonal eosinophils.<xref ref-type="bibr" rid="article-21092.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-21092.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hypereosinophilic syndrome is a rare disorder with an annual incidence of 0.36 to 6.3 per 100,000 patients.<xref ref-type="bibr" rid="article-21092.r6">[6]</xref>&#x000a0;This condition most commonly occurs in people&#x000a0;aged 20&#x000a0;to 50 years. However, children may also be affected&#x02014;particularly those with immunodeficiencies.<xref ref-type="bibr" rid="article-21092.r7">[7]</xref>&#x000a0;Cardiac involvement is present in 50% of the cases and is more common in males; however, a close variant, endomyocardial fibrosis, affects both sexes equally. Loeffler endocarditis is rare in North America and primarily includes temperate and tropical areas of Asia, Africa, and some of South America.&#x000a0;</p>
      </sec>
      <sec id="article-21092.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of Loeffler endocarditis is common to the spectrum of hypereosinophilic syndrome. The basic event is eosinophil-mediated cell injury. Interleukin-5 is a cytokine that is specific for eosinophil differentiation. Interleukin-5, interleukin-3, and granulocyte-macrophage colony-stimulating factors work in the maturation and differentiation of eosinophils from myeloid progenitor cells.&#x000a0;</p>
        <p>The overproduction of eosinophils results from either the over-production of cytokines or the proliferation of clonal eosinophils secondary to defects in hematopoietic stem cells or signal transduction responsible for eosinophil production. The net dysregulation in eosinophil production and maturation results in enhanced biological activity of eosinophils and consequently damages cells.&#x000a0;</p>
        <p>When eosinophils infiltrate the heart, the protein granules secreted damage the endocardium and myocardium by producing direct toxins, activating platelets. The activated platelets later combine to form intracavitary and intravascular thrombi, leading to further damage to the endocardium. Other mechanisms include the activation of Von Willebrand factor<bold>,&#x000a0;</bold>a large glycoprotein in the blood, and coagulation factor XII, which may disrupt endothelial lining that enhances the procoagulant activity and activates fibrin production.</p>
      </sec>
      <sec id="article-21092.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The biopsy is the mainstay of diagnosis but requires invasive intervention. Light microscopy shows degranulated eosinophils and eosinophil cationic protein in the endocardium and activated eosinophils at the myocardial interstitium. On electron microscopy, characteristic cardiac changes from myocytolysis showing disruption at the intercellular junctions are observed.<xref ref-type="bibr" rid="article-21092.r8">[8]</xref>&#x000a0;The endocardium of one or both ventricles typically has fibrosis and thickening, affecting the underlying myocardium. Large mural thrombi may develop in the right or left ventricle, resulting in reduced ventricular cavity size, a potential source of pulmonary and systemic emboli.<xref ref-type="bibr" rid="article-21092.r9">[9]</xref>&#x000a0;Histological features also comprise inflammation of the small intramural coronary vessels.</p>
      </sec>
      <sec id="article-21092.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History</bold>
</p>
        <p>Patients with&#x000a0;Loeffler endocarditis may present with signs and symptoms of acute or chronic heart failure, including dyspnea on exertion or rest, easy fatiguability, orthopnea, and paroxysmal nocturnal dyspnea. Patients may present with constitutional symptoms such as unintentional weight loss or fatigue. Cardiac symptoms include palpitations, chest pain, presyncope, or syncope in patients with arrhythmia. Patients with valvular abnormalities present with symptoms of valvular heart disease, such as mitral regurgitation and aortic insufficiency.&#x000a0;</p>
        <p>The chief complaint is shortness of breath, reported in 60% of cases. Rare cases present with symptoms and signs of pericarditis (4%).<xref ref-type="bibr" rid="article-21092.r10">[10]</xref>&#x000a0;Congestive heart failure may also develop in 38% of patients. Eosinophilic infiltration may cause valvular abnormality and most commonly involves the mitral valve, causing mitral valve insufficiency (42%). This condition can also involve the aortic wall leading to aortic stenosis and regurgitation, present in 4% of cases.</p>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>On examination, patients have signs of biventricular failure, including elevated jugular venous pressure, pulmonary rales, congested liver, limb edema, third heart sound, and Kussmaul signs&#x000a0;may be seen. Hepatomegaly and ascites may also be seen in advanced cases. Pulse is irregular in the presence of atrial fibrillation. Patients with end-stage disease may have cachexia and jaundice.&#x000a0;</p>
      </sec>
      <sec id="article-21092.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Noninvasive diagnostic modalities have emerged as initial tools for diagnosing patients with Loeffler&#x000a0;endocarditis.</p>
        <p><bold>CBC&#x000a0;</bold>usually reveals persistent hyper-eosinophilia (&#x0003e;1.5 x 10/L) on at least 2 occasions.</p>
        <p><bold>An electrocardiogram&#x000a0;</bold>may show non-specific ST-T changes, T-wave inversions, left atrial enlargement, left ventricular hypertrophy, incomplete right bundle branch block, left axis deviation, or evidence of bundle branch block. Atrial fibrillation and premature atrial and ventricular contractions may also be seen. There is no single pathognomic electrocardiogram finding of Loeffler endocarditis.</p>
        <p><bold>2-D transthoracic echocardiogram&#x000a0;</bold>is universally the initial choice of investigation. Findings depend on the stage of the disease and are usually inconspicuous in the initial necrotic stage of the disease. Endomyocardial thickening and mural thrombi can be appreciated as the disease progresses. A thrombus in the ventricle apex and the absence of apical akinesia should prompt suspicion of the disease. In earlier stages, apical thrombi in the ventricles can be confused with an apical variant of hypertrophic cardiomyopathy. However, a layered structure with different degrees of echogenicity suggests the possibility of a thrombus rather than the hypertrophied apex. The obliterated apex gives a classical 'kissing ventricle' appearance on apical views. In the third stage, the fibrotic endocardium appears brighter (with greater echo) than the rest of the myocardium; this is seen by focusing on the apex, magnifying the image, and adjusting gain.<xref ref-type="bibr" rid="article-21092.r11">[11]</xref>&#x000a0;Shaper, et al, described the variable degree of endocardial involvement of the disease. One may see the involvement of apex alone, apex to valve, sub-valvular apparatus, apex, and valvular apparatus with intervening normal myocardium or patchy distribution.<xref ref-type="bibr" rid="article-21092.r12">[12]</xref>&#x000a0;In advanced stages, features of restrictive cardiomyopathy are noted. These include diastolic dysfunction, bi-atrial enlargement, and a small left ventricle cavity, albeit preserved ejection fraction. Any grade of diastolic dysfunction can be noted in Loeffler&#x000a0;endocarditis.</p>
        <p>The atrioventricular valve involvement results in thickened, fibrotic valves and regurgitation. There may be involvement of chordae and restricted/tethered mobility of valve leaflets, resulting in eccentric regurgitation. Pericardial effusion can be seen in 10% to 32% of patients with hypereosinophilic syndromes.<xref ref-type="bibr" rid="article-21092.r11">[11]</xref>&#x000a0;</p>
        <p><bold>3-D transthoracic echocardiogram</bold>&#x000a0;shows progressive circumferential/concentric obliteration of the LV cavity as one sees from base to apex. Through a multi-slice view, the extent of involvement can be fully appreciated. A 3D transthoracic echocardiography with contrast after multi-slice reconstruction can show the exact location and extent of the thrombus. The normal myocardium will appear opacified (perfused), whereas the thrombus will appear dark (nonperfused).<xref ref-type="bibr" rid="article-21092.r11">[11]</xref>&#x000a0;</p>
        <p><bold>Cardiac magnetic resonance imaging&#x000a0;</bold>has emerged as a robust, non-invasive imaging modality that helps detect the disease earlier, with good sensitivity and specificity, providing exact differentiation of the viable myocardium, fibrosis, thrombus, edema, or necrosis. The pivotal role of cardiac magnetic resonance imaging in&#x000a0;Loeffler endocarditis is its ability to accurately assess right ventricle involvement, tissue characterization, detection of smaller thrombi, and early detection of even subtle endocardial involvement. The late gadolinium-enhanced images show typical sub-endocardial hyperenhancement at the top of the thrombus, not restricted to the distribution of one coronary artery, patchy or diffuse, extending up to inflow and sub-valvular region, in some cases. This pattern in the absence of obstructive coronary artery disease is characteristic of Loeffler endocarditis. Additionally, this imaging helps differentiate the stage of the disease, such as myocardial edema, on T-2 weighted images, which is suggestive of the inflammatory (acute) stage.</p>
        <p>In contrast, the absence of edema and late gadolinium-enhanced images suggest a late stage of the disease. Contrast-enhanced images help demarcate ventricular thrombus. Cardiac magnetic resonance imaging accurately assesses right ventricular function and size in 3D. Some experts have used cardiac magnetic imaging to monitor therapy response in Loeffler endocarditis, while others have used this imaging to increase the yield of endomyocardial biopsy by targeted sampling.<xref ref-type="bibr" rid="article-21092.r13">[13]</xref>&#x000a0;There is some evidence that the quantification of late gadolinium-enhanced images by cardiac magnetic resonance imaging is an independent predictor of mortality in Loeffler endocarditis.<xref ref-type="bibr" rid="article-21092.r14">[14]</xref></p>
        <p><bold>Cardiac computerized tomography for Loeffler</bold>&#x000a0;endocarditis is limited due to its inability to provide hemodynamic assessment, radiation exposure, use of nephrotoxic contrast agents, and lower temporal resolution compared to echocardiogram and cardiac magnetic resonance. However, computerized tomography may be useful in patients with poor acoustic windows or contraindications to cardiac magnet resonance. While computerized tomography may not help with the initial necrotic stage of the disease, this imaging can detect the presence and extent of the thrombus. Thrombi usually appear iso-dense; with contrast enhancement, thrombi remain non-enhanced.&#x000a0;</p>
        <p><bold>Endomyocardial biopsy&#x000a0;</bold>is the gold standard diagnostic modality for eosinophilic endocarditis. However, this modality is reserved for patients with diagnostic uncertainty due to its invasive nature. Findings on endomyocardial biopsy depend on the stage of the disease. In the acute necrotic stage, endomyocardial biopsy demonstrates eosinophil-mediated myocardial damage, even without eosinophils; this is performed by staining antibodies to eosinophil granule proteins, such as major basic protein 1.<xref ref-type="bibr" rid="article-21092.r15">[15]</xref>&#x000a0;Thick and loose collagen filaments may be seen.&#x000a0;</p>
        <p><bold>Molecular testing&#x000a0;</bold>is recommended for all patients with suspected hypereosinophilic syndromes&#x000a0;for&#x000a0;<italic toggle="yes">FIP1L1-PDGFRA.</italic>&#x000a0;Further evaluation of hypereosinophilic syndromes&#x000a0;also includes T-lymphocyte phenotyping and bone marrow aspiration.&#x000a0;</p>
      </sec>
      <sec id="article-21092.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Limited data exists regarding the outcomes of suggested treatment strategies for Loeffler endocarditis; however, the following measures can be taken:</p>
        <list list-type="bullet">
          <list-item>
            <p>Symptomatic management of Loeffler&#x000a0;endocarditis can be achieved with supportive care with diuretics, digoxin, and conventional therapy for heart failure, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-adrenergic blockers, and aldosterone antagonists.</p>
          </list-item>
          <list-item>
            <p>Rate control for atrial fibrillation and diuretics are the mainstay of treatment.</p>
          </list-item>
          <list-item>
            <p>Therapeutic pleural or ascitic tap can be performed as needed.</p>
          </list-item>
          <list-item>
            <p>There is no indication of prophylactic anticoagulation in Loeffler&#x000a0;endocarditis per se. However, anticoagulation should be started if a ventricular thrombus is diagnosed via echocardiography or CMR. Warfarin or low molecular weight heparin can be used in patients with Loeffler&#x000a0;endocarditis with ventricular thrombus or when a mechanical mitral valve is implanted.</p>
          </list-item>
          <list-item>
            <p>Treatment of the underlying hypereosinophilic syndromes&#x000a0;should be started as soon as the diagnosis is made. Steroids are the first-line therapy for hypereosinophilic syndromes due to their anti-inflammatory effect. Hydroxyurea can be used as a second-line agent, depending on the condition's etiology. All patients diagnosed with hypereosinophilic syndromes&#x000a0;with or without cardiac involvement should have genetic testing for&#x000a0;<italic toggle="yes">FIP1L1-PDGFRA</italic>&#x000a0;mutation, which can affect disease management. Patients positive for this mutation should be treated with imatinib, a tyrosine kinase inhibitor, which has provided a good treatment response in the literature.</p>
          </list-item>
          <list-item>
            <p>Surgical options include endomyocardial resection and valve replacement or repair. Patients with Loeffler&#x000a0;endocarditis may need mitral valve replacement due to mitral regurgitation. Data on outcomes are limited. Tricuspid valve surgery is associated with increased postsurgical mortality (15%-30%). The mitral valve can be replaced with either a mechanical or bioprosthetic valve, but a biological valve is preferable due to a high incidence of mechanical valve thrombosis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21092.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses to consider and rule out include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Restrictive cardiomyopathy of any cause (amyloidosis, sarcoidosis)</p>
          </list-item>
          <list-item>
            <p>Diastolic dysfunction due to hypertensive heart disease</p>
          </list-item>
          <list-item>
            <p>Churg-Strauss syndrome</p>
          </list-item>
          <list-item>
            <p>Giant cell myocarditis</p>
          </list-item>
          <list-item>
            <p>Medication-induced hypersensitivity reaction</p>
          </list-item>
          <list-item>
            <p>Tropical endomyocardial fibrosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21092.s11" sec-type="Staging">
        <title>Staging</title>
        <p>There are 3 pathological stages of Loeffler endocarditis. Cardiac symptoms predominantly occur in Stages 2 and 3.<xref ref-type="bibr" rid="article-21092.r16">[16]</xref>&#x000a0;</p>
        <p><bold>Stage 1:</bold>&#x000a0;Acute endo-myocardial inflammation/necrosis (first 1-2 months) resulting in eosinophilic infiltration with degranulation and release of toxic proteins. Pathologically, there is myocardial damage and sterile microabscesses. This is usually a silent stage. Minor elevation in troponin and splinter or conjunctival hemorrhages may be found.<xref ref-type="bibr" rid="article-21092.r17">[17]</xref>&#x000a0;On diagnostic evaluation, echocardiography is usually normal. Cardiac magnetic imaging resonance helps in describing early eosinophilic-mediated myocardial involvement in the form of subendocardial hyperenhancement. Endomyocardial biopsy<bold>&#x000a0;</bold>is the gold standard test for demonstrating eosinophil-mediated myocardial damage, even without eosinophils; this is done by staining antibodies to eosinophil granule proteins, such as major basic protein 1.&#x000a0;</p>
        <p><bold>Stage 2:</bold>&#x000a0;Thrombotic stage (after about 10 months) resulting in endothelial damage and thrombus formation. There may be valve motion restriction. The eosinophil peroxidase forms hypothiocyanous acid, which induces the formation of tissue factors in endothelial cells. Eosinophils may also directly release tissue factors. The consequence is the formation of an endocardial thrombus. Patients in this stage are at heightened risk of thromboembolic events, such as stroke or limb ischemia.<xref ref-type="bibr" rid="article-21092.r18">[18]</xref>&#x000a0;</p>
        <p><bold>Stage 3:</bold>&#x000a0;Fibrotic stage (after 1-2 years), where the thrombi are replaced by fibrosis. The endomyocardium, valves, and chordae tendineae are involved. This stage is associated with restrictive cardiomyopathy and valve incompetence.<xref ref-type="bibr" rid="article-21092.r19">[19]</xref><xref ref-type="bibr" rid="article-21092.r20">[20]</xref>&#x000a0;In this final fibro-inflammatory stage, patients manifest with signs and symptoms of right or left heart failure. Echocardiography usually shows obliteration of the ventricle apex. Cardiac magnetic resonance imaging shows extensive subendocardial hyperenhancement, characteristic of the disease. There may be evidence of myocardial damage secondary to coronary vasculitis and infarction.&#x000a0;</p>
      </sec>
      <sec id="article-21092.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Steroid responders have a better prognosis than non-responders. Due to the rare nature of the disease, clear evidence about&#x000a0;long-term morbidity and mortality is lacking.&#x000a0;</p>
      </sec>
      <sec id="article-21092.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Complications can include&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Restrictive cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Ventricular apical mural thrombosis</p>
          </list-item>
          <list-item>
            <p>Systemic and coronary embolism (stroke, myocardial infarction, renal infarct)</p>
          </list-item>
          <list-item>
            <p>Splenic infarction</p>
          </list-item>
          <list-item>
            <p>Mitral valve regurgitation</p>
          </list-item>
          <list-item>
            <p>Aortic valve regurgitation or stenosis</p>
          </list-item>
          <list-item>
            <p>Tricuspid valve disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21092.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Limited evidence of a definitive management strategy exists for this disease. There is also a need for long-term data on patient outcomes and survival. Patients might suffer delays in diagnosis due to the rare nature of the disease and the limited experience of clinicians diagnosing this disease. Meticulous volume management and drug adjustment are often required. An interprofessional team approach is needed for optimal patient outcomes.&#x000a0;</p>
      </sec>
      <sec id="article-21092.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Loeffler endocarditis is a rare disorder. Without treatment, the disease is progressive and bears poor outcomes. An interprofessional team that includes a cardiologist, cardiac imaging specialist, cardiac surgeon, rheumatologist, internist, and cardiac care nurse is ideal for managing this condition. Surgical therapy has variable results; operator and center experience dealing with the disease affects&#x000a0;the outcomes. Diagnosing LE earlier and closely following up with patients, even if they are asymptomatic, is&#x000a0;important. Based on isolated case reports, most patients with LE have good to excellent outcomes.<xref ref-type="bibr" rid="article-21092.r2">[2]</xref><xref ref-type="bibr" rid="article-21092.r21">[21]</xref></p>
        <p>An interprofessional team comprising a cardiologist, cardiac imaging specialist, cardiac surgeon, rheumatologist, internist, and cardiac care nurses, and therapists care for patients with this cardiac condition across the care continuum. This diverse team collaborates seamlessly to enhance the recognition and management of Loeffler endocarditis, contributing to improved patient outcomes. Their collective expertise ensures a comprehensive approach, covering various aspects of Loeffler endocarditis care and addressing the unique challenges posed by this condition.</p>
      </sec>
      <sec id="article-21092.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21092&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21092">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/loeffler-endocarditis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21092">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21092/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21092">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21092.s17">
        <title>References</title>
        <ref id="article-21092.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dregoesc</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Iancu</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Balanescu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Hypereosinophilic syndrome with cardiac involvement in a patient with multiple malignancies.</article-title>
            <source>Med Ultrason</source>
            <year>2018</year>
            <month>Aug</month>
            <day>30</day>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>399</fpage>
            <page-range>399-400</page-range>
            <pub-id pub-id-type="pmid">30167597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Loeffler endocarditis as a rare cause of heart failure with preserved ejection fraction: A case report and review of literature.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>97</volume>
            <issue>11</issue>
            <fpage>e0079</fpage>
            <pub-id pub-id-type="pmid">29538200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allderdice</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marcu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kabirdas</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Intracardiac Thrombus in Leukemia: Role of Cardiac Magnetic Resonance Imaging in Eosinophilic Myocarditis.</article-title>
            <source>CASE (Phila)</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>114</fpage>
            <page-range>114-117</page-range>
            <pub-id pub-id-type="pmid">30062326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cardiac involvements in hypereosinophilia-associated syndrome: Case reports and a little review of the literature.</article-title>
            <source>Echocardiography</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>8</issue>
            <fpage>1242</fpage>
            <page-range>1242-1246</page-range>
            <pub-id pub-id-type="pmid">28573678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doyen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Buscot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dellamonica</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Endomyocardial fibrosis complicating primary hypereosinophilic syndrome.</article-title>
            <source>Intensive Care Med</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>12</issue>
            <fpage>2294</fpage>
            <page-range>2294-2295</page-range>
            <pub-id pub-id-type="pmid">30006894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boggild</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Keystone</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kain</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Tropical pulmonary eosinophilia: a case series in a setting of nonendemicity.</article-title>
            <source>Clin Infect Dis</source>
            <year>2004</year>
            <month>Oct</month>
            <day>15</day>
            <volume>39</volume>
            <issue>8</issue>
            <fpage>1123</fpage>
            <page-range>1123-8</page-range>
            <pub-id pub-id-type="pmid">15486834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farruggia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>D'Angelo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Acquaviva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trizzino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tucci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cilloni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Messa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>D'Ambrosio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aric&#x000f2;</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hypereosinophilic syndrome in childhood: clinical and molecular features of two cases.</article-title>
            <source>Pediatr Hematol Oncol</source>
            <year>2009</year>
            <season>Apr-May</season>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>129</fpage>
            <page-range>129-35</page-range>
            <pub-id pub-id-type="pmid">19382034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Isobe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okubo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sekiguchi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Improvement of eosinophilic heart disease after steroid therapy: successful demonstration by endomyocardial biopsied specimens.</article-title>
            <source>Heart Vessels</source>
            <year>1999</year>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>104</fpage>
            <page-range>104-8</page-range>
            <pub-id pub-id-type="pmid">10651187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottdiener</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Schooley</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Harley</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Fauci</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Two-dimensional echocardiographic assessment of the idiopathic hypereosinophilic syndrome. Anatomic basis of mitral regurgitation and peripheral embolization.</article-title>
            <source>Circulation</source>
            <year>1983</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>572</fpage>
            <page-range>572-8</page-range>
            <pub-id pub-id-type="pmid">6821899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thampi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saba</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Jermyn</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Loeffler Endocarditis: A Unique Presentation of Right-Sided Heart Failure Due to Eosinophil-Induced Endomyocardial Fibrosis.</article-title>
            <source>Clin Med Insights Case Rep</source>
            <year>2017</year>
            <volume>10</volume>
            <fpage>1179547617723643</fpage>
            <pub-id pub-id-type="pmid">28890659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polito</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Hagendorff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Citro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Prota</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Silverio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Angelis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Klingel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Metze</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>St&#x000f6;be</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Sabri</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Piscione</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Galasso</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Loeffler's Endocarditis: An Integrated Multimodality Approach.</article-title>
            <source>J Am Soc Echocardiogr</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>12</issue>
            <fpage>1427</fpage>
            <page-range>1427-1441</page-range>
            <pub-id pub-id-type="pmid">33129649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaper</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Hutt</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Coles</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Necropsy study of endomyocardial fibrosis and rheumatic heart disease in Uganda 1950-1965.</article-title>
            <source>Br Heart J</source>
            <year>1968</year>
            <month>May</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>391</fpage>
            <page-range>391-401</page-range>
            <pub-id pub-id-type="pmid">5651254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Syed</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Glockner</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease.</article-title>
            <source>Int J Cardiol</source>
            <year>2008</year>
            <month>Jun</month>
            <day>06</day>
            <volume>126</volume>
            <issue>3</issue>
            <fpage>e50</fpage>
            <page-range>e50-2</page-range>
            <pub-id pub-id-type="pmid">17399811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salemi</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Rochitte</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Shiozaki</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Parga</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>de &#x000c1;vila</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Benvenuti</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Cestari</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Picard</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Mady</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients.</article-title>
            <source>Circ Cardiovasc Imaging</source>
            <year>2011</year>
            <month>May</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>304</fpage>
            <page-range>304-11</page-range>
            <pub-id pub-id-type="pmid">21415124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wright</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Leiferman</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Gleich</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Eosinophil granule protein localization in eosinophilic endomyocardial disease.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Jul</month>
            <day>14</day>
            <volume>365</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-8</page-range>
            <pub-id pub-id-type="pmid">21751935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weller</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Bubley</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>The idiopathic hypereosinophilic syndrome.</article-title>
            <source>Blood</source>
            <year>1994</year>
            <month>May</month>
            <day>15</day>
            <volume>83</volume>
            <issue>10</issue>
            <fpage>2759</fpage>
            <page-range>2759-79</page-range>
            <pub-id pub-id-type="pmid">8180373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Arrigo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Azzarello</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>La Gattuta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Amata</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Righi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coglitore</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.</article-title>
            <source>Blood</source>
            <year>2003</year>
            <month>Nov</month>
            <day>01</day>
            <volume>102</volume>
            <issue>9</issue>
            <fpage>3456</fpage>
            <page-range>3456-7; author reply 3457</page-range>
            <pub-id pub-id-type="pmid">14568908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Mahmud</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Geng</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Key</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Slungaard</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states.</article-title>
            <source>Blood</source>
            <year>2006</year>
            <month>Jan</month>
            <day>15</day>
            <volume>107</volume>
            <issue>2</issue>
            <fpage>558</fpage>
            <page-range>558-65</page-range>
            <pub-id pub-id-type="pmid">16166591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hernandez</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Arisha</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oates</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nanda</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Nanda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wasan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caleti</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Bernal</surname>
                <given-names>CLP</given-names>
              </name>
              <name>
                <surname>Gallardo</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Usefulness of three-dimensional echocardiography in the assessment of valvular involvement in Loeffler endocarditis.</article-title>
            <source>Echocardiography</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>7</issue>
            <fpage>1050</fpage>
            <page-range>1050-1056</page-range>
            <pub-id pub-id-type="pmid">28600838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ogbogu</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Rosing</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Horne</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular manifestations of hypereosinophilic syndromes.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>457</fpage>
            <page-range>457-75</page-range>
            <pub-id pub-id-type="pmid">17868859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21092.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Dramatic and early response to low-dose steroid in the treatment of acute eosinophilic myocarditis: a case report.</article-title>
            <source>BMC Cardiovasc Disord</source>
            <year>2017</year>
            <month>May</month>
            <day>08</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <pub-id pub-id-type="pmid">28482853</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
